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ABSTRACT

Objectives Cardiovascular complications became a
notable cause of morbidity and mortality in patients
with lupus as therapeutic advancements became
more efficient at managing other complications. The
Appalachian community in Kentucky has a higher
prevalence of traditional cardiovascular risk factors,
predisposing them to cardiovascular events. Namely,
the mean body mass index of the members of the
Kentucky Appalachian community was reported
at 33 kg/m2 and 94.3% of male members of this
community use tobacco. We sought to identify
risk factors that predispose patients with lupus to
cardiovascular morbidities and examine the effect of
immunomodulatory drugs.
Methods We identified 20 UKHS patients having
both a lupus diagnosis and experienced at least one
cardiovascular event. We chose three controls matched
for birth-year ±5 years to each case. In a case–
control design, we analysed lupus manifestations,
cardiovascular risk factors and immunosuppressive
therapies. We collected Systemic Lupus Erythematosus
Disease Activity Index 2000 disease activity index
during the cardiovascular event.
Results We identified 308 patients with lupus from
among all University of Kentucky Health System patients.
20 (6.5%) of such patients with lupus were confirmed
to cardiovascular complication. Of those 20, 7 (35%)
had experienced myocardial infarction, 10 (50%) had
experienced stroke and 4 (20%) had peripheral ischaemia.
Tobacco use and male gender were the only traditional
cardiovascular risk factors higher in the cases group.
Hydroxychloroquine and steroids were less utilised
in the cases than in the controls (70% vs 100% in
hydroxychloroquine, 30% vs 82% in steroids). Venous
thrombosis was found to be significantly higher in the
cases. On multivariate analysis, venous thrombosis
remained significant.
Conclusion Despite tobacco use partially explaining the
increased risk of cardiovascular disease among the cases
group, the higher prevalence of venous thrombosis in the
cases group suggests lupus as a potential additional risk
factor of cardiovascular morbidity among patients with
lupus in this Appalachian community.

Key messages
What is already known about this subject?
►► Lupus is a known contributor to increased risk of

cardiovascular morbidity.
What does this study add?
►► Traditional cardiovascular risk factors, especially

tobacco use, should be addressed in patients with
lupus .
How might this impact on clinical practice or future
developments?
►► Among patients with lupus with venous thrombosis,
clinicians should be alert to the higher risk of cardiovascular complications, particularly stroke.
►► Among patients with arterial thrombovascular disease, venous thrombosis should alert clinicians to
consider the presence of underlying lupus.

INTRODUCTION
SLE is a multisystem autoimmune disease with
high morbidity.1 Classically, disease mortality
was attributed to renal involvement.1 As
immunomodulatory therapy improved, renal-
related mortality was reduced.1–3 Cardiovascular mortality has become a more prominent cause of mortality,4 making up 30% of
mortality in the first 5 years after diagnosis.5–7
Both stroke and myocardial infarction were
noted to occur more often in premenopausal
lupus women compared with their counterparts.1 5–10 Average age at which such events
occurred in comparison to general population was younger (49 vs 69 years).6 The
risk of cardiovascular disease in lupus is not
completely accounted for by traditional cardiovascular risk factors.8 11 The increased risk is
not restricted to myocardial infarctions and
stroke but also includes peripheral arterial
disease.12
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of cardiovascular risk factors and atherosclerosis versus
lupus disease activity and subclinical vasculitis in different
populations.
METHODS
Patient population
Through search of the University of Kentucky Health
System (UKHS) database, including inpatient and outpatient medical records for the years 2004 through 2020, we
identified 308 patients having diagnosis codes of ICD-9
(710-Connective tissue disease, unspecified) or (Lupus
erythematosus 695.4) or ICD-10 (M32 Systemic lupus
erythematosus) or (L93 Lupus erythematosus). Among
these patients, only those who received treatment with
hydroxychloroquine and/or had two or more visits with
University of Kentucky Rheumatology Clinic were selected
for further study. The hydroxychloroquine treatment
criteria was added to capture newly added UKHS patients
who had previously received outpatient rheumatology
treatment outside of that system. Since some relevant
individuals might not have been captured if treatment
with hydroxychloroquine had been contraindicated, we
elected to expand the search by including individuals
who were provided at least one follow-up visit with the
UKHS Rheumatology Clinic as a more reliable indicator
of a true diagnosis of systemic autoimmunity. All patients
included in this study fulfill the American College of
Rheumatology classification criteria by reviewing documentation in medical records.33
We screened the 308 UKHS patients with lupus for
atherosclerosis (ICD-9 440.2, ICD-10 I70), coronary
artery disease (ICD-9 414.01, ICD-10 I20-I25, I00-I99) and
peripheral arterial disease (ICD-9 443.9, ICD-10 I73.9),
which identified 20 patients as our cases group of patients
with lupus having cardiovascular complications. Three
of the UKHS patients with lupus that had not exhibited any cardiovascular complications were matched
with each member of the cases group by birth year ±5
years as controls to increase the power of the study. The
codes encompassed events occurring within the University of Kentucky or historically, particularly when events
occurred in external systems. Follow-up post lupus diagnosis ranged between 1 year and 41 years, as earliest diagnosis was 1979 and latest was 2019.
We searched the medical records of the cases and
control groups for traditional cardiovascular risk factors
including tobacco use, diabetes mellitus, hypertension,
dyslipidaemia and obesity. We recorded lupus manifestations at baseline and at the time of cardiovascular events.
These included malar rash, arthritis, other lupus rashes,
alopecia, mucocutaneous ulceration, pleuritis, pericarditis, neuropsychiatric manifestations, renal involvement, Raynaud’s phenomenon and sicca symptoms. We
collected information regarding laboratory test results for
these patients, including leucopenia, thrombocytopenia,
lymphopenia, leukouria, haematuria, proteinuria, red cell
casts, C3 and C4 complements levels, anti-double-stranded
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In Appalachian communities, cardiovascular events are
increased compared with the rest of the USA. Particularly,
Kentucky ranked sixth in 2003 on total cardiovascular
age-
adjusted death rate.13 According to the American
Heart Association, the state of Kentucky has one of the
highest death rates in both stroke and coronary artery
disease. Kentucky is ranked 42nd in the nation, with first
ranked state reflecting lowest death rate from stroke and
coronary artery disease.14
It is noteworthy that traditional cardiovascular risk
factors are increased in this population, with overall
average body mass index (BMI) of 33 kg/m2 and tobacco
use reaching up to 94.3% in male members of the population.15 Therefore, addressing all potential risk factors
of cardiovascular disease among Kentucky Appalachian
patients with lupus is imperative. Among traditional
cardiovascular risk factors in patients with lupus, several
studies have demonstrated important associations.
Namely, peripheral arterial disease was associated with
higher risk of cardiovascular endpoints.16 Additionally,
dyslipidaemia,17 metabolic syndrome,18 older age at diagnosis and longer duration of cardiovascular disease were
also associated with high risk of cardiovascular adverse
events.9 19 In contrast, among other studies, particularly
in Europe10 20 and Canada,18 lupus itself and its manifestations were identified as risk factors for cardiovascular
disease in patients with lupus. Namely, arthritis, pleuritis,
venous thrombosis, neuropsychiatric disease manifestations and antiphospholipid antibodies were identified as
important predictors.6 20
Response to immunosuppressive treatments differed
among studies and medications. In a study on peripheral
ischaemia in lupus, Erdozain et al12 noted that patients
with lupus with normal ankle-brachial index had a higher
chance of being on cyclophosphamide. This raised the
question that perhaps cyclophosphamide may have been
protective of peripheral arterial disease in this studied
population. However, hydroxychloroquine did not show
this potential beneficial effect.12 Yet, other studies have
shown a reduction of cardiovascular disease in hydroxychloroquine users.21 In regard to steroids, a study on all
cardiovascular end points, mean duration of steroid use
was correlated with higher risk.9
Cardiovascular disease pathogenesis in lupus was
explained by either atherosclerosis and/or subclinical
vasculitis. Ultrasonographic carotid intima-media thickness, as a proven predictor of myocardial infarction events
in lupus, was used as surrogate of atherosclerosis.22–29 A
multination study, utilising angiography as a surrogate for
atherosclerosis, did not show atherosclerosis as predictor
of cardiovascular disease in patients with lupus.30 In
autopsy-
based studies, both accelerated atherosclerosis
and vasculitis were noted on histopathology of coronary
vasculature.31 32 These findings might partially justify
why studies differ in the type of risk factors (traditional
cardiovascular vs lupus manifestations) and response
to immunosuppressive therapies. Therefore, further
studies need to delineate the magnitude of contribution

Co-m orbidities

Statistical analysis
χ2 test was used for categorical variables, while the Shapiro-
Wilks test was used when the assumption of normality
was not fulfilled. Equal variance t-tests for continuous
variables were used to compare case versus control at
baseline. We evaluated the association between the cardiovascular outcomes (stroke, myocardial infarction and
peripheral ischaemic event) and aforementioned lupus
clinical manifestations, serological testing and traditional
cardiovascular risk factors using univariate analysis. Multivariate logistic regression was done using all variables
and their two-way interactions as possible predictors for
forward selection using the rFSA R package to check for
interactions. Throughout the analyses, a p value<0.05 was
considered statistically significant.
RESULTS
We identified 308 UKHS patients with lupus fulfilling aforementioned ICD-9/10 code at the University of Kentucky
in addition to either use of hydroxychloroquine and/or
having two or more visits with Rheumatology between the
years 2004 and 2020. Among the 308 patients with lupus
identified, we found 20 (6.7%) patients who had cardiovascular complications. In comparison, the University
of Pittsburgh Registry demonstrated that 23/498 (4.7%)
patients developed myocardial infarction.8 Among these
20 individuals, 7 (35%) had myocardial infraction, 10
(50%) had stroke and 4 (20%) had peripheral ischaemia.
One patient had both a cardiovascular complication and
stroke. Out of the 20 patients with SLE with cardiovascular disease, 15 (75%) were Caucasian and 5 (25%) were
African American (table 1). The mean SLEDAI-2K score
among the cases group at the time of cardiovascular event
was 11.15±9.25, with most common associated manifestation being thrombocytopenia at 6 (30%), followed by
low complements at 5 (25 %) and elevated dsDNA at
4 (20%). Excluding neuropsychiatric manifestations,
SLEDAI score would be reduced to 9.35±5.68.
Among the seven patients who developed coronary
artery disease, three of these patients, all of which were
tobacco users, underwent Coronary Artery Bypass Graft.
The average age at lupus diagnosis of all the individuals

Table 1 Active lupus manifestations prior to cardiovascular
end event
Active features

Frequency

SLEDAI-2K score

11.15±9.25

Percentage

Any lupus rash

1

5

Arthritis

2

10

Serositis

1

5

Renal disease

2

10

Neuropsychiatric

2

10

Leucopenia

3

15

Thrombocytopenia

6

30

Low complements

5

25

Elevated anti-dsDNA

4

20

dsDNA, double stranded DNA; SLEDAI-2K, Systemic Lupus
Erythematosus Disease Activity Index 2000.

developing myocardial infarction was 45.4 years. Among
the patients with single-vessel disease involvement, two
had right coronary artery involvement and one had left
anterior descending artery involvement. Tobacco use was
a risk factor in 4/7 (57%) myocardial infarction patients
(online supplemental table 1). The mean age at diagnosis
of myocardial infarction was 51.43±8.43.
Among patients who had a stroke, average age in
patients with lupus was 30.9 years, which is around 15
years younger than lupus diagnosis in the myocardial
infarction group. Tobacco use was a risk factor present
in 4 (40%) of the 10 patients who had a stroke. Two
patients had multi-infarct disease, both of whom were
diagnosed with lupus in their 20’s and neither of whom
was a tobacco user. The mean of age of stroke diagnosis
was 38±11.97, which is 13 years younger than the mean
age of occurrence of myocardial infarction. (p=0.0297)
(online supplemental table 2).
Among the individuals who had suffered a myocardial infarction, three patients suffered that event prior
to their lupus diagnosis. Per records, these were initially
attributed to traditional risk factors such as obesity
(online supplemental table 1). Among the individuals
who had experienced one or more strokes, one patient
was diagnosed with lupus after stroke diagnosis and this
was initially attributed to traditional risk factors of hypertension and obesity (online supplemental table 2). A
prior study at University of Toronto noted myocardial
infarction occurred early at onset of lupus or prior to
diagnosis.8
Among patients with peripheral ischaemic vascular
disease, only one was a tobacco user. Two of the peripheral ischaemia patients were diagnosed with lupus in their
teenage years, one of whom was diagnosed with both
lupus and peripheral ischaemia at a young age (online
supplemental table 3).
We controlled for baseline therapy by focusing on the
therapies given to the cases group prior to occurrence of
a cardiovascular event. All patients of the control group
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DNA antibodies, anti-
Smith antibodies, anti-
RNP antibodies, anti-
SSA antibodies, anti-
SSB antibodies, lupus
anticoagulant, anti-
cardiolipin antibodies and anti-β2
glycoprotein antibodies. Systemic Lupus Erythematosus
Disease Activity Index 2000 (SLEDAI-2K) was collected at
the time of event for the cases.
We also collected information regarding any immunomodulatory disease-
modifying agents that had been
administered to patients of the study cohort (with such
administration being before the occurrence of cardiovascular events for patients of the cases group). Such
agents included steroids, azathioprine, mycophenolate
mofetil, rituximab, cyclophosphamide, belimumab and
hydroxychloroquine.

Lupus Science & Medicine
Table 2 Treatments given prior to cardiovascular events versus treatments given in control group
Cases (n=20)

Controls (n=60)

OR (CI)

P value

6/20

49/60

0.10 (0.03 to 0.31)

<0.001*†

14/20

60/60

Not applicable

<0.001†

Azathioprine

6/20

17/60

1.08 (0.36 to 3.29)

0.89

Mycophenolate mofetil

5/20

18/60

0.78 (0.25 to 2.46)

0.67

Cyclophosphamide

3/20

6/60

1.59 (0.36 to 7.04)

0.54

Rituximab

3/20

3/60

3.35 (0.62 to 18.16)

0.14

Belimumab

1/20

4/60

0.74 (0.08 to 7.01)

0.79

Steroids
Hydroxychloroquine

*Remained significant in multivariate analysis.
†Bold indicates statistical significance.

had been treated with hydroxychloroquine, while only
70% (14/20) of the cases group had been treated with
hydroxychloroquine. Steroid use was also lower in the
cases group. None of the other disease-modifying agents
were found to have protective effect or different utilisation between the cases and the controls (table 2).
On univariate analysis, the cases group had less arthritis
reported (table 3). Among the other lupus risk factors,
only venous thrombosis was higher in the cases group,
which persisted through multivariate analysis (table 4).
Among the traditional cardiovascular risk factors, tobacco
use was higher in the cases group, but did not persist into
multivariate analysis.
Among the six patients who had venous thrombosis,
four had strokes and two had peripheral ischaemia. Four
of the six venous thrombosis patients were diagnosed with
lupus at an age below 45 years and two of such patients
were diagnosed after 45 years of age. Three of the six
venous thrombosis patients were tobacco users (online
supplemental table 4).
DISCUSSION
SLE has been associated with an increased risk of adverse
cardiovascular events. However, the risk of cardiovascular
events among a high-risk population such as the Appalachian population is not well understood. To our knowledge, this is the first study on cardiovascular morbidity
risk factors among Appalachian patients with lupus. In a
prospective lupus cohort, several risk factors were found
to be predictive of a first cardiovascular event including
arthritis, pleuritis and venous thrombosis.20 We found
similar correlation in venous thrombosis and association with cardiovascular morbidity. As we analysed our
cases with venous thrombosis, they were mainly patients
who developed strokes and peripheral ischaemia rather
than myocardial infarction. Generally, we show in our
study trends towards higher traditional cardiovascular
risk factors in the cases group, particularly using tobacco
showing statistical significance (only on univariate analysis). Similarly, results from the University of Toronto
lupus cohort identified tobacco as a risk factor for cardiovascular end points (myocardial infarction (MI), stroke
and peripheral ischaemia).6 Appalachian communities
4

are at higher risk of cardiovascular morbidity.34 For
instance, a 2020 study noted an average BMI of 33 kg/
m2 in the Kentucky Appalachian community with a
concerning 94.3% tobacco use among men.15
Beyond showing the contribution of traditional cardiovascular risk factors, we were able to identify venous
thrombosis as significantly higher in cases with adverse
cardiovascular events compared with controls.35 In view
of this result, we believe it is important that clinicians be
vigilant in regarding a new diagnosis of lupus as a risk
factor for stroke and regard lupus as a potential risk factor
for early stroke, particularly in patients with history of
venous thrombosis.6 20 36 Nonetheless, we show some cases
who developed myocardial infarction or stroke prior to
lupus diagnosis in our study. Initially, those events were
attributed to traditional risk factors. Prior study from the
University of Toronto showed myocardial infarction prior
to or early on after diagnoses of lupus.37
Our cases had mean SLEDAI-2K score of 11.15 prior to
the event. A prospective study evaluating stroke in lupus
found an SLEDAI-2K of 12.6 on average in comparison
with 8.4 in control group.38 Hinting that even in the
Appalachian community, which has high level of traditional cardiovascular risk factors, lupus activity remains
a contributing factor for stroke. Prior studies supported
our findings, namely the Framingham score, fell short of
predicting cardiovascular morbidity in patients with lupus
indicating lupus-related risk.8 11
Our study shows lower steroid use in cases with adverse
cardiovascular events compared with controls in contrast
to a prior study which showed higher steroid use.9
However, we measured steroids use as a dichotomous
value in comparison with the Hopkins cohort who utilised
duration of steroid use.9 Steroid use is a risk of cardiovascular disease but can lead to lower lupus disease activity.
A possible explanation is that, at initial doses, steroid
use reduces disease activity but when such use is excessive the benefit of disease control is offset by steroid side
effects such as obesity. Additionally, our study is in 2020 in
comparison with the 1992 study.9 The use of steroids could
possibly be higher in 1992 compared with 2020, as rheumatologists are becoming more aggressive with disease-
modifying agents. In relation to immunosuppression, a

McVeigh ED, et al. Lupus Science & Medicine 2021;8:e000467. doi:10.1136/lupus-2020-000467

Lupus Sci Med: first published as 10.1136/lupus-2020-000467 on 5 May 2021. Downloaded from http://lupus.bmj.com/ on May 7, 2021 by guest. Protected by copyright.

Treatment

Co-m orbidities
Table 3 Comparison of patients with cardiovascular events and the control group (univariate analysis)
Cases (n=20)

Controls (n=60)

OR (CI)

P value

Malar rash

2/20

11/60

0.49 (0.10 to 2.45)

0.38

Any lupus rash

9/20

28/60

0.94 (0.34 to 2.58)

0.90

Mucocutaneous ulcers

2/20

11/60

0.49 (0.10 to 2.45)

0.38

Sicca

6/20

17/60

1.08 (0.36 to 3.29)

0.89

Alopecia

4/20

11/60

1.11 (0.31 to 3.99)

0.87

Arthritis

5/20

34/60

0.25 (0.08 to 0.79)

0.01†

Serositis

4/20

7/60

1.89 (0.49 to 7.30)

0.35

Pericarditis

3/20

5/60

1.94 (0.42 to 8.98)

0.39

Pleuritis

1/20

2/60

1.53 (0.13 to 17.79)

0.73

DAH

1/20

0/60

Renal disease

7/20

19/60

Neuropsychiatric

1/20

1/60

Raynaud’s

5/20

16/60

Leucopenia
Thrombocytopenia
Haemolysis
Low complement
Anti-dsDNA

Not applicable

0.08

1.16 (0.40 to 3.38)

0.78

3.10 (0.19 to 52.08)

0.40

0.92 (0.29 to 2.93)

0.88

11/20

32/60

1.07 (0.39 to 2.96)

0.90

9/20

25/60

1.15 (0.41 to 3.18)

0.79

3/20

2/60

12/20

29/60

5.12 (0.79 to 33.17)

0.06

1.60 (0.57 to 4.48)

0.37

6/18

32/59

0.42 (0.14 to 1.27)

0.12

12/16

25/50

3 (0.85 to 10.58)

0.08

Anti-SSB

2/15

10/50

Anti-Smith

4/15

8/52

Anti-RNP

7/14

21/53

Venous thrombosis

6/20

4/60

Anti-SSA

0.62 (0.12 to 3.18)

0.56

2 (0.51 to 7.87)

0.32

1.52 (0.47 to 4.98)

0.48

6 (1.49 to 24.19)

0.006*†

Pregnancy loss

1/17

2/58

1.75 (0.15 to 20.56)

0.65

Livedo reticularis

0/20

1/60

Not applicable

0.56

Seizure

5/20

5/60

3.67 (0.94 to 14.35)

0.05

Anti-β2GPI IgG

0/12

0/32

Not applicable

0.00

Anti-β2GPI IgM

2/12

1/32

6.2 (0.51 to 75.84)

0.11

Cardiolipin IgG

2/14

2/34

2.67 (0.34 to 21.12)

0.34

Cardiolipin IgM

1/14

1/34

2.54 (0.15 to 43.67)

0.51

Lupus anticoagulant
BMI>30

4/13

5/32

2.4 (0.53 to 10.93)

0.25

11/20

22/60

2.11 (0.76 to 5.89)

0.15

Diabetes

2/20

3/60

Dyslipidaemia

8/20

15/60

2.11 (0.33 to 13.64)

0.42

1.83 (0.63 to 5.30)

0.26

Hypertension

10/20

28/60

1.14 (0.42 to 3.15)

0.80

Tobacco

11/20

14/60

4.01 (1.38 to 11.65)

0.008†

Female gender

13/20

58/60

0.064 (0.01 to 0.34)

0.0001*†

*Remained significant in multivariate analysis.
†Bold indicates statistical significance.
BMI, body mass index; DAH, diffuse alveolar haemorrhage; dsDNA, double-stranded DNA; β2GPI, β-2 glycoprotein I; RNP,
ribonucleoprotein; SSA, Sjögren syndrome A; SSB, Sjögren syndrome B.

Table 4 Logistic regression predicting case
Term

Estimate

P value

Female

−1.61

0.0016

Steroids

−1.42

0.0003

0.063 (0.012 to 0.342)

1.51

0.0032

18.690 (2.250 to 155.243)

Venous clot

OR (95% CI)
0.034 (0.003 to 0.371)

study focused on peripheral ischaemia showed potential correlation between cyclophosphamide as protective against peripheral vascular disease, but this was not
demonstrated with hydroxychloroquine.12 In contrast,
we have found that hydroxychloroquine use was significantly lower in the cases group indicating possible
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hydroxychloroquine treatment criteria was intended to
catch patients with lupus who were followed at Rheumatology clinics outside the University of Kentucky Rheumatology Clinic.
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Statistical significance of this manifestation was found
despite the high prevalence of cardiovascular risk factors
in our cases, particularly using tobacco, and overall higher
cardiovascular risk factors in Appalachian communities.15
In regard to medications, we showed the potential benefit
of hydroxychloroquine on reducing cardiovascular events
as seen in prior analyses.21 We showed a lower steroid use
in the cases which contrasts with higher mean duration
use of steroids in a prior study among individuals with
cardiovascular events.9
Therefore, rheumatologists should be vigilant with
cessation of tobacco use counselling in patients with
lupus. Neurologists and clinicians caring for new patients
who had a stroke should consider lupus as risk factors,
especially in younger patients, even in the presence of
other risk factors. We further note that, despite being
generally regarded as a mainstay of therapy in all patients
with lupus, hydroxychloroquine is still not prescribed
consistently in clinical practice. In view of the potential
benefit of hydroxychloroquine in reducing cardiovascular
events, hydroxychloroquine initiation threshold should
be lowered, particularly in patients who have other traditional risk factors or had venous thrombosis.

Co-m orbidities
26 Souza AWSde, Hatta FS, Miranda F, et al. Atherosclerotic plaque
in carotid arteries in systemic lupus erythematosus: frequency and
associated risk factors. Sao Paulo Med J 2005;123:137–42.
27 Telles RW, Lanna CCD, Ferreira GA, et al. Carotid atherosclerotic
alterations in systemic lupus erythematosus patients treated at a
Brazilian university setting. Lupus 2008;17:105–13.
28 Eder L, Gladman DD, Ibañez D, et al. The correlation between carotid
artery atherosclerosis and clinical ischemic heart disease in lupus
patients. Lupus 2014;23:1142–8.
29 Kao AH, Lertratanakul A, Elliott JR, et al. Relation of carotid
intima-media thickness and plaque with incident cardiovascular
events in women with systemic lupus erythematosus. Am J Cardiol
2013;112:1025–32.
30 Urowitz MB, Gladman D, Ibañez D, et al. Atherosclerotic vascular
events in a multinational inception cohort of systemic lupus
erythematosus. Arthritis Care Res 2010;62:881–7.
31 Panchal L, Divate S, Vaideeswar P, et al. Cardiovascular involvement
in systemic lupus erythematosus: an autopsy study of 27 patients in
India. J Postgrad Med 2006;52:5-10; discussion 10.
32 Kazzaz NM, Wilson AM, Kado R, et al. A 37-year-old man with
primary antiphospholipid syndrome presenting with respiratory
distress and worsening toe ischemia. Arthritis Care Res
2017;69:1253–9.
33 Hochberg MC. Updating the American College of rheumatology
revised criteria for the classification of systemic lupus
erythematosus. Arthritis Rheum 1997;40:1725.
34 Esch L, Hendryx M. Chronic cardiovascular disease mortality in
mountaintop mining areas of central Appalachian states. J Rural
Health 2011;27:350–7.
35 Bertolaccini ML, Amengual O, Andreoli L, et al. 14Th international
Congress on antiphospholipid antibodies Task force. Report on
antiphospholipid syndrome laboratory diagnostics and trends.
Autoimmun Rev 2014;13:917–30.
36 Bessant R, Duncan R, Ambler G, et al. Prevalence of conventional
and lupus-specific risk factors for cardiovascular disease in patients
with systemic lupus erythematosus: a case-control study. Arthritis
Rheum 2006;55:892–9.
37 Urowitz MB, Gladman DD, Anderson NM, et al. Cardiovascular
events prior to or early after diagnosis of systemic lupus
erythematosus in the systemic lupus international collaborating
clinics cohort. Lupus Sci Med 2016;3:e000143.
38 Mikdashi J, Handwerger B, Langenberg P, et al. Baseline disease
activity, hyperlipidemia, and hypertension are predictive factors for
ischemic stroke and stroke severity in systemic lupus erythematosus.
Stroke 2007;38:281–5.

McVeigh ED, et al. Lupus Science & Medicine 2021;8:e000467. doi:10.1136/lupus-2020-000467

7

Lupus Sci Med: first published as 10.1136/lupus-2020-000467 on 5 May 2021. Downloaded from http://lupus.bmj.com/ on May 7, 2021 by guest. Protected by copyright.

12 Erdozain JG, Villar I, Nieto J, et al. Peripheral arterial disease in
systemic lupus erythematosus: prevalence and risk factors. J
Rheumatol 2014;41:310–7.
13 Rugg SS, Bailey AL, Browning SR. Preventing cardiovascular disease
in Kentucky: epidemiology, trends, and strategies for the future. J Ky
Med Assoc 2008;106:149-61; quiz 149, 162-3.
14 Thom T, Haase N, Rosamond W, et al. Heart disease and
stroke statistics--2006 update: a report from the American
Heart Association Statistics Committee and Stroke Statistics
Subcommittee. Circulation 2006;113:e85–151.
15 Abraham CM, Kelly S, Wantland D, et al. Factors influencing
cardiovascular risk factors and health perception among Kentuckians
living in Appalachia. J Cardiovasc Nurs 2020;35:E1–8.
16 Leng GC, Lee AJ, Fowkes FG, et al. Incidence, natural history
and cardiovascular events in symptomatic and asymptomatic
peripheral arterial disease in the general population. Int J Epidemiol
1996;25:1172–81.
17 Bhatt SP, Handa R, Gulati GS, et al. Peripheral vascular disease in
systemic lupus erythematosus. Lupus 2007;16:720–3.
18 Bultink IEM, Turkstra F, Diamant M, et al. Prevalence of and risk
factors for the metabolic syndrome in women with systemic lupus
erythematosus. Clin Exp Rheumatol 2008;26:32–8.
19 Bruce IN, Gladman DD, Urowitz MB. Premature atherosclerosis
in systemic lupus erythematosus. Rheum Dis Clin North Am
2000;26:257–78.
20 Gustafsson J, Gunnarsson I, Börjesson O, et al. Predictors of
the first cardiovascular event in patients with systemic lupus
erythematosus - a prospective cohort study. Arthritis Res Ther
2009;11:R186.
21 Liu D, Li X, Zhang Y, et al. Chloroquine and hydroxychloroquine are
associated with reduced cardiovascular risk: a systematic review and
meta-analysis. Drug Des Devel Ther 2018;12:1685–95.
22 Manzi S, Selzer F, Sutton-Tyrrell K, et al. Prevalence and risk factors
of carotid plaque in women with systemic lupus erythematosus.
Arthritis Rheum 1999;42:51–60.
23 Roman MJ, Salmon JE, Sobel R, et al. Prevalence and relation to
risk factors of carotid atherosclerosis and left ventricular hypertrophy
in systemic lupus erythematosus and antiphospholipid antibody
syndrome. Am J Cardiol 2001;87:663–6.
24 Svenungsson E, Jensen-Urstad K, Heimbürger M, et al. Risk
factors for cardiovascular disease in systemic lupus erythematosus.
Circulation 2001;104:1887–93.
25 Roman MJ, Shanker B-A, Davis A, et al. Prevalence and correlates of
accelerated atherosclerosis in systemic lupus erythematosus. N Engl
J Med 2003;349:2399–406.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

Lupus Sci Med

Supplemental:
Table 1 Supplemental: Myocardial infarction cases
Age during
event
48
43
50
39
62
55

Age at Lupus
Diagnosis
51
39
52
30
64
32

Coronaries involved and/or
intervention
CABG
Not documented
RCA
LAD, CABG
Not documented, CABG
RCA

Traditional risk factors

Tobacco user and obese
Dyslipidemia, HTN, and obese
Dyslipidemia and Obese
Tobacco user, diabetes, and HTN
Dyslipidemia, tobacco user, and HTN
Dyslipidemia, tobacco user and
obese
63
50
Not documented
Dyslipidemia, tobacco user and HTN
LAD, Left anterior descending; RCA, right coronary artery; PDA, posterior descending artery; CABG,
coronary artery bypass graft
Italic: also had stroke
Table 2 supplemental: Stroke cases
Age during Age at Lupus Vessels involved
Traditional risk factors
event
Diagnosis
26
23
Unknown
Tobacco user, HTN, and obese
27
39
Right MCA
HTN and obese
58
46
Right PCA
HTN
28
28
Right MCA
Tobacco user
44
44
Unknown
HTN and obese
24
24
Right occipital & thalamic
Diabetic, HTN, and Obese
58
27
MCA
Tobacco user, HTN, and obese
37
20
Multi-cerebellar & thalamic
Nil
35
35
Unknown
Obese
43
21
Left PCA
Tobacco user and obese
HTN, Hypertension; PCA, posterior cerebral artery; MCA, Middle cerebral artery
Italic: also had myocardial infarction

Table 3 supplemental: Peripheral ischemic disease cases
Age during
event
55
70
22

Age at Lupus
Diagnosis
17
49
18

Blood vessels involved

Traditional risk factors

Left posterior tibial artery
Unknown
Feet digits

NIL
Hypertension
Tobacco user and obese
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Table 4 supplemental: Individuals who had venous thrombosis
Age at Lupus Diagnosis
46
18
17
27
35
21

Age at first event
58
22
55
58
35
43

Events
Stroke
Peripheral Ischemia
Peripheral Ischemia
Stroke
Stroke
Stroke

Tobacco user
No
Yes
No
Yes
No
Yes

Table 5 supplemental: Demographics of cases vs controls
Parameter
Mean age at lupus Diagnosis
Female gender
Caucasian
Black
Asian
Hispanic

Cases
36.3
13/20 (65%)
15/20 (75%)
5/20 (25%)
0/20 (0%)
1/20 (5%)

Controls
37.43
58/60 (97%)
42/60 (70%)
17/60 (28%)
1/60 (2%)
0/20 (0%)
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